Only two in ten eligible patients receive CAR-T: closing the gap starts in manufacturing
Only around 20% of eligible US patients currently receive CAR-T therapy. Drawing on the Cell & Gene Therapy Insights CAR-T Special Interest Group, this infographic examines the manufacturing barriers behind that gap and compares three routes to wider access: autologous, allogeneic, and in vivo CAR-T.
Authors
- no authors
Publication Details
- Journal
- Cell and Gene Therapy Insights
- Published
- 2026-10-08
- DOI
- https://doi.org/10.18609/cgti.2026.117
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00